Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
| Revenue (TTM) | $22.23B |
| Gross Profit (TTM) | $10.47B |
| EBITDA | $6.16B |
| Operating Margin | 14.70% |
| Return on Equity | 6.67% |
| Return on Assets | 4.38% |
| Revenue/Share (TTM) | $77.99 |
| Book Value | $87.58 |
| Price-to-Book | 1.80 |
| Price-to-Sales (TTM) | 1.87 |
| EV/Revenue | 2.7 |
| EV/EBITDA | 12.08 |
| Quarterly Earnings Growth (YoY) | 28.60% |
| Quarterly Revenue Growth (YoY) | 5.20% |
| Shares Outstanding | $275.54M |
| Float | $274.74M |
| % Insiders | 0.42% |
| % Institutions | 98.98% |
Volatility is currently expanding
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Becton, Dickinson and Company delivered solid Q2 2026 results, with EPS of $2.90 beating estimates by $0.13. Revenue reached $4.7B, exceeding consensus by $30M and marking a 5.2% YoY increase post-spin-off of BD Life Sciences & Diagnostic Solutions. The company boasts a few high-margin, high-growth product lines that should fuel a return to sustainable growth.
Becton, Dickinson and Company is undervalued, trading at 12–13x P/E despite forecasted 7%–8% annual growth and improving fundamentals. BDX's sector-wide pressures are driven by cautious hospital spending, higher rates, and capital rotation into AI, but its core operations remain robust. BDX maintains a BBB rating, conservative leverage, a 2.78% dividend with 44+ years of increases, and is executing $2B in buybacks while retiring $2.1B in debt.
Recognition from Vizient validates CentroVena One™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety FRANKLIN LAKES, N.J., June 23, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®, the nation's largest provider-driven healthcare performance improvement company.
Despite facing some headwinds, these three companies still have strong long-term prospects. All three have raised their payouts for more than 50 consecutive years.
Representative Thomas H. Kean Jr, a Republican from New Jersey who sits on the House Energy and Commerce Committee, has disclosed four new congressional stock trades.
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Becton, Dickinson's MedTech focus, innovation push and strategic partnerships support growth optimism, though reimbursement uncertainty remains a key concern.
BDX launches the Elyra Thulium Fiber Laser system to streamline kidney stone care and boost workflow flexibility for urology teams.
New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures. FRANKLIN LAKES, N.J.
